• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

The 7 Pillars of Healthcare Strength

Here are healthcare stocks of all shares and sizes with strong charts.
By JIM CRAMER
Mar 23, 2015 | 06:00 AM EDT
Stocks quotes in this article: BIIB, OC, ASH, AMGN, BMRN, CELG, REGN, VRTX, ALXN, PCYC, ISIS, BMY, LLY, ABC, MCK, CAH, AET, ANTM, CI, HUM, UNH, ACT, BDX, MDT, MNK, TMO, HSIC, SRCL, DGX, PRGO, TEVA, MYL, CERN, WBA, CVS, RAD

You know how you could have -- and may still -- handily beat the averages?

Simply develop a portfolio of healthcare companies of all shapes and sizes that do nothing but try to service the colossus that is the American medical system.

As I peruse the charts this weekend, it almost seems too easy. There's simply nothing like this group. Oh sure, there are the companies that do well in a low-energy regime: hotels, restaurants, retailers, truckers and even the derivative plays like Owens Corning (OC) and Ashland (ASH). These are stocks that everyone knows except those who still believe that the additional dollars aren't being spent. That non-spend thesis has kept you out of the second-best group of stocks for certain.

But it is pretty unbelievable how much money has poured into the healthcare sector.

We all know this is the era when Amgen (AMGN), BioMarin (BMRN), Biogen-Ideec (BIIB), Celgene (CELG), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Pharmacyclics (PCYC), Isis Pharma (ISIS) and so many other biotechs became the darlings of a lower-growth lower-interest-rate environment. A combination of voracious large capitalization drug stocks not having a real pipeline to keep up with their generic cliffs and the creation of blockbuster drugs from years of research has propelled this group.

(Check out Trifecta Stocks' Bob Lang's latest technical analysis of CEL, ISIS and CVS and chart work of Real Money Pro's Gary Berman's on AGMN. Also, Real Money Pros's Rob Moreno IDs two biotech that may be ripe for a short.)

Amgen (AMGN)
Source: FreeStockCharts.com
View Chart » View in New Window »
BioMarin Pharman (BMRN)
Source: FreeStockCharts.com
View Chart » View in New Window »
Biogen-Idec (BIIB)
Source: FreeStockCharts.com
View Chart » View in New Window »
Celgene (CELG)
Source: FreeStockCharts.com
View Chart » View in New Window »
Regeneron (REGN)
Source: FreeStockCharts.com
View Chart » View in New Window »
Vertex (VRTX)
Source: FreeStockCharts.com
View Chart » View in New Window »
Alexion (ALXN)
Source: FreeStockCharts.com
View Chart » View in New Window »
Pharmacyclics (PCYC)
Source: FreeStockCharts.com
View Chart » View in New Window »
ISIS Pharma (ISIS)
Source: FreeStockCharts.com
View Chart » View in New Window »

The only outliers in old pharma, at least when it comes to the charts, are Bristol-Myers (BMY) and Lilly (LLY), the former a re-rating of an old line drug company to a fast-growing one and the latter just a plain out-and-out mystery to me, an overvalued stock that never comes in.

Bristol-Myers (BMY)
Source: FreeStockCharts.com
View Chart » View in New Window »
Eli Lilly (LLY)
Source: FreeStockCharts.com
View Chart » View in New Window »

Beyond biotechs, the second group that astounds remains the companies that rein in costs to the system: AmerisourceBergen (ABC), McKesson (MCK) and Cardinal Health (CAH) continue to dominate. These stocks never quit and the analysts' love for them never stops. These are perhaps the most amazing stocks of the era because what they do is so obvious and they do it so consistently that it's almost like these stocks were created for stock market performance.

AmerisourceBergen (ABC)
Source: FreeStockCharts.com
View Chart » View in New Window »
McKesson (MCK)
Source: FreeStockCharts.com
View Chart » View in New Window »
Cardinal Health (CAH)
Source: FreeStockCharts.com
View Chart » View in New Window »

The third group health group that never seems to stop delivering, despite endless attempts by analysts to call the top? The health maintenance organizations that turned out to be the biggest winners of the Affordable Care Act: Aetna (AET), Anthem (ANTM), Cigna (CI), Humana (HUM) and UnitedHealth (UNH). I don't even know if it is worth distinguishing them anymore. I have had such a hard time with these because I have repeatedly thought they were done or had to have run out of gas. The charitable trust got a fantastic move out of Cigna and it turned out we got a small fraction of what this company's stock has given you.

Aetna (AET)
Source: FreeStockCharts.com
View Chart » View in New Window »
Anthem (ANTM)
Source: FreeStockCharts.com
View Chart » View in New Window »
Cigna (CI)
Source: FreeStockCharts.com
View Chart » View in New Window »
Humana (HUM)
Source: FreeStockCharts.com
View Chart » View in New Window »
UnitedHealth (UNH)
Source: FreeStockCharts.com
View Chart » View in New Window »

As we are basically in inning two of the Affordable Care Act and it is now unlikely to be rolled back, it is reasonable to think that these stocks aren't even done going higher, especially when you consider that Aetna and Cigna trade at discounts to the S&P 500 at 15x earnings! Don't forget these are also levered to increased employment in the country. So they are doubly blessed.

The fourth group? Those that have augmented their fortunes through mergers: Actavis (ACT), Becton Dickinson (BDX), Medtronic (MDT), Mallinckrodt (MNK), and Thermo Fisher (TMO). These companies have many years of earnings growth ahead either because of they are now inverted (Actavis and Medtronic) or because their acquisitions have so much synergy. These stocks are miracles, frankly, with Actavis being the best example. I have spent some time with CEO Brent Saunders and was initially a tad skeptical because I have not particularly liked what look like roll-ups. But calling Actavis a roll-up seems almost insulting now.

Actavis (ACT)
Source: FreeStockCharts.com
View Chart » View in New Window »
Becton Dickinson (BDX)
Source: FreeStockCharts.com
View Chart » View in New Window »
Medtronic (MDT)
Source: FreeStockCharts.com
View Chart » View in New Window »
Mallinckrodt (MNK)
Source: FreeStockCharts.com
View Chart » View in New Window »
Thermo Fisher (TMO)
Source: FreeStockCharts.com
View Chart » View in New Window »

The fifth group: the suppliers and ancillary service companies. Here I prefer Henry Schein (HSIC), just added to the S&P 500, Laboratory (LH), Stericycle (SRCL) and Quest Diagnostics (DGX). These stocks seem to have no roof on them whatsoever. The stock market always loves this kind of company because we are always doing more testing and more examining and that makes these stocks ideal.

Henry Schein (HSIC)
Source: FreeStockCharts.com
View Chart » View in New Window »
Laboratory (LH)
Source: FreeStockCharts.com
View Chart » View in New Window »
Stericycle (SRCL)
Source: FreeStockCharts.com
View Chart » View in New Window »
Quest Diagnostics (DGX)
Source: FreeStockCharts.com
View Chart » View in New Window »

Sixth, there are the companies that are perceived as saving the system money: Perrigo (PRGO), Teva (TEVA), Mylan (MYL) and Cerner (CERN). The first three are generic drug companies that have been on fire of late and the third is the consistent supplier of healthcare solutions. Perrigo has always been my favorite because of its unique combination of knock-offs and prescription drugs. I have traditionally not liked Teva or Mylan because they, chiefly, are commodity players. But I now feel that I have become too much of a snob as this rising tide is lifting all boats.

Perrigo (PRGO)
Source: FreeStockCharts.com
View Chart » View in New Window »
Teva (TEVA)
Source: FreeStockCharts.com
View Chart » View in New Window »
Mylan (MYL)
Source: FreeStockCharts.com
View Chart » View in New Window »

Finally, seventh, there are the drugstore chains, Walgreens Boots Alliance (WBA), CVS Health (CVS) and Rite Aid (RAD). The first is at the beginning of internationalization, the second is the pioneer of new paradigm (a retail healthcare company) and the latter is attempting to be the next CVS with its recent acquisition of a pharmacy benefit manager.

Walgreen Boots Alliance (WBA)
Source: FreeStockCharts.com
View Chart » View in New Window »
CVS Health (CVS)
Source: FreeStockCharts.com
View Chart » View in New Window »
Rite Aid (RAD)
Source: FreeStockCharts.com
View Chart » View in New Window »

Now, of course, I have left out a ton of stocks in this survey course of the group. And I have chosen to highlight only the ones that hit me by looking at the best charts over the weekend. But you need to focus on this list because if we are going to have a selloff related to a slowdown of some sort the buyers will come right back to this group and its seven pillars of strength.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, is long TMO and WBA.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

Cooper Cos. Can Rally Further After Some Sideways Consolidation

Bruce Kamich
Dec 5, 2019 2:42 PM EST

Time to review the charts and indicators.

This Dividend Stock Is Tipping the Scales for Investors

Chris Versace
Dec 5, 2019 2:08 PM EST

As more Americans struggle with obesity, Medifast sees strength in weight-loss offerings.

Avita Medical Could Double in 2020 but Not Without Risk

Bruce Kamich
Dec 5, 2019 9:53 AM EST

A 'promising' stock.

Raise Stops on NovoCure

Bruce Kamich
Dec 4, 2019 2:55 PM EST

NVCR's prices are poised to head higher in the months ahead.

UNH Passes Checkup, but Not With Flying Colors

Timothy Collins
Dec 3, 2019 1:42 PM EST

Despite fluff and puff of UNH's analysts' day, little here screams for getting in right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:06 PM EST CAROLYN BORODEN

    MRK and LVS Targets Coming Up

    View Chart » View in New Window »  LVS View C...
  • 12:01 PM EST BOB LANG

    Rolling up Apple

    just the other day we added some apple calls on th...
  • 12:24 PM EST GARY BERMAN

    Fibocall: The SPX-Cash Long-Term View

    You will hear from many analysts on TV screaming t...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2019 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login